<div class="white-sheet">
    <div class="content-slide">

<!-- Secondary scene 1 -->
    <div class="content secondary-scene">
        <!--<h1>Content</h1>-->
        

                <div class="title-bar red"></div>

                <div class="wrapper slide-3-2-3">

                    <div class="vertical-nav">
                        <ul class="two">
                            <li class="active"></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references1-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>          
                        <div data-effect="fade" data-duration="1000" data-target="information1-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>    
                    </div>

                    <div class="slide-title red">
                        Rationale for eltrombopag use in aplastic anaemia
                    </div>


                    <div class="content-container">
                
                        <ul>
                            <li><span>Eltrombopag interacts with the transmembrane domain of the human TPO-R and initiates signalling cascades that induce proliferation and differentiation of megakaryocytes from bone marrow progenitor cells<sup>1,2</sup></span>
                                <ul>
                                    <li><span>Effects may occur despite elevated levels of TPO<sup>3</sup></span></li>
                                    <li><span>The different binding sites of eltrombopag and TPO on the TPO-R prevents competitive binding and potentially allows both molecules to have an additive effect on cell signalling<sup>4</sup></span></li>
                                    <li><span>Eltrombopag activity is dependent on TPO-R expression because no activity has been shown in cells expressing receptors for other haematopoietic growth factors, including EPO and granulocyte colony-stimulating factor (G-CSF)<sup>4</sup></span></li>
                                </ul>
                            </li>
                            <li><span>A lack of response to IST may be due to the limited number of haematopoietic stem cells<sup>5</sup></span>
                                <ul>
                                    <li><span>Treatment with a combination of IST with growth factors (e.g. G-CSF and EPO) was proposed to overcome the limited response to IST alone, but this approach is of limited use<sup>6</sup></span></li>
                                    <li><span>This may be due to growth factors acting on more committed stem cells, rather than on early-stage progenitors<sup>7</sup></span></li>
                                </ul>
                            </li>
                            <li><span>The ability of TPO to act on less-differentiated progenitor cells suggests that TPO-R agonists may be effective in the treatment of diseases associated with bone marrow failure, such as SAA<sup>7</sup></span></li>
                        </ul>


                    </div>

                </div>

                <div class="information1-overlay overlay">
            
                    <header>Rationale for eltrombopag use in aplastic anaemia</header>
                    
                    <ul>
                        <li><span>Studies showed that eltrombopag stimulated megakaryopoiesis in bone marrow cells from patients with myelodysplastic syndrome (MDS),8 a condition in which TPO levels are elevated, although to a lesser extent than in patients with aplastic anaemia<sup>9</sup></span></li>
                        <li><span>Clinical trials of haematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), stem cell factor and interleukin-3 have not demonstrated efficacy in aplastic anaemia<sup>7</sup></span>
                            <ul>
                                <li><span>Cytokine receptors are not present on primitive stem cells</span></li>
                                <li><span>Endogenous erythropoietin and G-CSF levels are highly elevated in SAA</span></li>
                            </ul>
                        </li>
                        <li><span>Preclinical evidence supports a potential role for TPO-R agonists in the treatment of cytopenias arising from bone marrow failure</span>
                            <ul>
                                <li><span>Eltrombopag accelerated the expansion of HSCs/HPCs in human umbilical cord blood cells in an in vivo mouse model<sup>10</sup></span></li>
                                <li><span>Multilineage haematopoiesis was also observed with eltrombopag<sup>10</sup></span></li>
                                <ul>
                                    <li><span>Circulating levels of human platelets and human white blood cells (WBCs) were increased</span></li>
                                </ul>
                            </ul>
                        </li>
                    </ul>

                </div>

                <div class="references1-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/module3/Revolade-SmPC-2012.pdf"><span>GSK. Revolade (eltrombopag). Summary of Product Characteristics. 2012</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module3/Promacta-PI-2014.pdf"><span>GSK. Promacta (eltrombopag). Prescribing Information (draft). 2014</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module3/OlnesM-2012-NEJM-v367p11.pdf"><span>Olnes M <i>et al. N Engl J Med</i> 2012;367:11</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module3/Erickson-MillerC-2009-StemCells-v27p424.pdf"><span>Erickson-Miller C <i>et al. Stem Cells</i> 2009;27:424</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module3/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Young NS. <i>Hematology Am Soc Hematol Educ Program</i> 2013;76</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module3/GurionR-2009-Haematologica-v94p712.pdf"><span>Gurion R <i>et al. Haematologica</i> 2009;94:712</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module3/MavroudiI-2011-LeukRes-v35p323.pdf"><span>Mavroudi I <i>et al. Leuk Res</i> 2011;35:323</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module3/FengX-2011-Haematologica-v96p602.pdf"><span>Feng X <i>et al. Haematologica</i> 2011;96:602</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module3/SunH-2012-StemCellRes-v9p77.pdf"><span>Sun H <i>et al. Stem Cell Res</i> 2012;9:77</span></li>
                    </ol>

                </div>

          
    </div>
    <!-- End of secondary scene 1 -->
    <!-- Secondary scene 2 (Static Content) -->
    <div class="content secondary-scene">
         

                <div class="title-bar blue"></div>

                <div class="wrapper slide-3-2-3a">

                    <div class="vertical-nav">
                        <ul class="two">
                            <li></li>
                            <li class="active"></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>          
                        <div data-effect="fade" data-duration="1000" data-target="information2-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>    
                    </div>

                    <div class="slide-title blue two-line">
                        Effect of eltrombopag on expansion of haematopoietic<br /> stem/progenitor cells and multilineage haematopoiesis
                    </div>


                    <div class="content-container">
                

                        <div class="content-left">
                            
                            <ul>
                                <li><span>An effect of eltrombopag on both human umbilical cord blood HSC expansion and haematopoiesis has been observed in preclinical studies</span>
                                    <ul>
                                        <li><span>Circulating levels of human platelets and WBCs were increased in a non-obese diabetic/severe combined immunodeficiency (NOD/SCID) xenotransplant mouse model <i>in vivo</i></span>
                                            <ul>
                                                <li><span>Expansion of human stem cells and progenitors in the bone marrow was enhanced with eltrombopag</span></li>
                                            </ul>
                                        </li>
                                        <li><span>Eltrombopag enhanced expansionof HSCs and megakaryocytes <i>in vitro</i></span></li>
                                    </ul>
                                </li>
                            </ul>

                        </div>

                        <div class="content-right">
                            
                            <div class="blue-label">Platelet and WBC levels in vivo (top) and expansion of cells<br /> in vitro with TPO or eltrombopag (bottom)</div>

                            <img src="media/images/slide_3-2-3/picture2.png" alt="">

                            <p class="small-print">Control=stem cell factor culture + FL growth factor; TPO=stem cell factor culture + FL growth factor + TPO; E=stem cell factor culture + FL growth factor+ eltrombopag</p>

                        </div>

                        

                    </div>

                </div>

                <div class="information2-overlay overlay">

                    <header>Effect of eltrombopag on expansion of haematopoietic stem/progenitor cells and multilineage haematopoiesis</header>
                        
                    <ul>
                        <li><span>The effect of eltrombopag on haematopoiesis of human umbilical cord blood stem cells and progenitor cells (CD34+) transplanted into immunodeficient mice was investigated</span>
                            <ul>
                                <li><span>Eltrombopag increased circulating levels of human platelets and WBCs compared with control, but had no effect on murine thrombopoiesis or WBC counts</span></li>
                                <li><span>Analysis of human cell surface markers on cells extracted from bone marrow revealed that HSCs/HPCs (CD34+), WBCs (CD45+) and cells from the thrombocyte lineage (CD41+) were all increased with eltrombopag versus control</span>
                                    <ul>
                                        <li><span>Proliferation of mouse bone marrow cells was not affected by treatment with eltrombopag</span></li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                    </ul>

                </div>


                <div class="references2-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/module3/SunH-2012-StemCellRes-v9p77.pdf"><span>Sun H <i>et al. Stem Cell Res</i> 2012;9:77</span></li>
                    </ol>

                </div>

          
    </div>
    <!-- End of secondary scene 2 -->

    </div>
 </div>